Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders
Nicoletta Cera,1,2 Stefania Bifolchetti,1,3 Giovanni Martinotti,1,2 Francesco Gambi,1,2 Gianna Sepede,1,2 Marco Onofrj,1,3 Massimo Di Giannantonio,1 Astrid Thomas1,31Department of Neuroscience and Imaging, “G. d'Annunzio” University, Chieti, Italy; 2ITAB-Institute for Ad...
Guardado en:
Autores principales: | , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d47b930d8f694c29ae878b3de2beb310 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:d47b930d8f694c29ae878b3de2beb310 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:d47b930d8f694c29ae878b3de2beb3102021-12-02T06:16:53ZAmantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders1178-2021https://doaj.org/article/d47b930d8f694c29ae878b3de2beb3102014-06-01T00:00:00Zhttp://www.dovepress.com/amantadine-and-cognitive-flexibility-decision-making-in-parkinson39s-p-a17226https://doaj.org/toc/1178-2021 Nicoletta Cera,1,2 Stefania Bifolchetti,1,3 Giovanni Martinotti,1,2 Francesco Gambi,1,2 Gianna Sepede,1,2 Marco Onofrj,1,3 Massimo Di Giannantonio,1 Astrid Thomas1,31Department of Neuroscience and Imaging, “G. d'Annunzio” University, Chieti, Italy; 2ITAB-Institute for Advanced Biomedical Technologies, Chieti, Italy; 3Aging Research Centre, Ce.S.I., “G. d'Annunzio” University Foundation, Chieti, ItalyIntroduction: Dopamine replacement therapy for Parkinson's disease (PD) was recently linked to the development of impulse control disorders such as pathological gambling (PG), hypersexuality, compulsive shopping, and binge or compulsive eating. Antiglutamatergic agents including amantadine (Ama) reduce these behaviors in PD and non-PD patients. The aim of our study is to evaluate the changes in executive functions, emotions, and reward/loss processing during Ama treatment in PD patients.Methods: Thirty-three patients affected by idiopathic PD were selected from a cohort of 1,096 PD patients and categorized in three different groups: ten affected by PG (PD-PG); nine PD patients with other impulse control disorder (PD-ICD); and 14 PD patient without any psychiatric disorder (PD-CTR-controls). For the neuropsychological evaluation, the following behavioral tasks where administered: the Stroop, the emotional Stroop, and the monetary reward/loss risk-taking tasks.Results: During Ama treatment, PD-PGs showed a decrease in risky choices and an increase in non-risky choices (t(9)=−2.40, P<0.05 and t(9)=2,67, P<0.05 uncorrected, respectively). Between-group comparison showed a significant decrease in risky choices for PD-PG with respect to PD-CTR (t(22)=−4.16, P<0.01), and a decreased accuracy for positive words in comparison between PD-PG and PD-ICD (t(17)=−7,49, P<0.01) and PD-PG and PD-CTR (t(22)=−4.29, P<0.01). No within- and between-group differences were observed for Stroop task.Discussion: Our data showed that Ama add-on therapy reduces hypersensitivity to reward and sustains activation toward uncertainty in PD-PG patients. These finding might explain the behavioral mechanism underlying the effect of antiglutamatergic drugs.Keywords: Parkinson’s disease, executive functions, emotion Cera NBifolchetti SMartinotti GGambi FSepede GOnofrj MDi Giannantonio MThomas ADove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2014, Iss default, Pp 1093-1101 (2014) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Cera N Bifolchetti S Martinotti G Gambi F Sepede G Onofrj M Di Giannantonio M Thomas A Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders |
description |
Nicoletta Cera,1,2 Stefania Bifolchetti,1,3 Giovanni Martinotti,1,2 Francesco Gambi,1,2 Gianna Sepede,1,2 Marco Onofrj,1,3 Massimo Di Giannantonio,1 Astrid Thomas1,31Department of Neuroscience and Imaging, “G. d'Annunzio” University, Chieti, Italy; 2ITAB-Institute for Advanced Biomedical Technologies, Chieti, Italy; 3Aging Research Centre, Ce.S.I., “G. d'Annunzio” University Foundation, Chieti, ItalyIntroduction: Dopamine replacement therapy for Parkinson's disease (PD) was recently linked to the development of impulse control disorders such as pathological gambling (PG), hypersexuality, compulsive shopping, and binge or compulsive eating. Antiglutamatergic agents including amantadine (Ama) reduce these behaviors in PD and non-PD patients. The aim of our study is to evaluate the changes in executive functions, emotions, and reward/loss processing during Ama treatment in PD patients.Methods: Thirty-three patients affected by idiopathic PD were selected from a cohort of 1,096 PD patients and categorized in three different groups: ten affected by PG (PD-PG); nine PD patients with other impulse control disorder (PD-ICD); and 14 PD patient without any psychiatric disorder (PD-CTR-controls). For the neuropsychological evaluation, the following behavioral tasks where administered: the Stroop, the emotional Stroop, and the monetary reward/loss risk-taking tasks.Results: During Ama treatment, PD-PGs showed a decrease in risky choices and an increase in non-risky choices (t(9)=−2.40, P<0.05 and t(9)=2,67, P<0.05 uncorrected, respectively). Between-group comparison showed a significant decrease in risky choices for PD-PG with respect to PD-CTR (t(22)=−4.16, P<0.01), and a decreased accuracy for positive words in comparison between PD-PG and PD-ICD (t(17)=−7,49, P<0.01) and PD-PG and PD-CTR (t(22)=−4.29, P<0.01). No within- and between-group differences were observed for Stroop task.Discussion: Our data showed that Ama add-on therapy reduces hypersensitivity to reward and sustains activation toward uncertainty in PD-PG patients. These finding might explain the behavioral mechanism underlying the effect of antiglutamatergic drugs.Keywords: Parkinson’s disease, executive functions, emotion |
format |
article |
author |
Cera N Bifolchetti S Martinotti G Gambi F Sepede G Onofrj M Di Giannantonio M Thomas A |
author_facet |
Cera N Bifolchetti S Martinotti G Gambi F Sepede G Onofrj M Di Giannantonio M Thomas A |
author_sort |
Cera N |
title |
Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders |
title_short |
Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders |
title_full |
Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders |
title_fullStr |
Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders |
title_full_unstemmed |
Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders |
title_sort |
amantadine and cognitive flexibility: decision making in parkinson's patients with severe pathological gambling and other impulse control disorders |
publisher |
Dove Medical Press |
publishDate |
2014 |
url |
https://doaj.org/article/d47b930d8f694c29ae878b3de2beb310 |
work_keys_str_mv |
AT ceran amantadineandcognitiveflexibilitydecisionmakinginparkinson39spatientswithseverepathologicalgamblingandotherimpulsecontroldisorders AT bifolchettis amantadineandcognitiveflexibilitydecisionmakinginparkinson39spatientswithseverepathologicalgamblingandotherimpulsecontroldisorders AT martinottig amantadineandcognitiveflexibilitydecisionmakinginparkinson39spatientswithseverepathologicalgamblingandotherimpulsecontroldisorders AT gambif amantadineandcognitiveflexibilitydecisionmakinginparkinson39spatientswithseverepathologicalgamblingandotherimpulsecontroldisorders AT sepedeg amantadineandcognitiveflexibilitydecisionmakinginparkinson39spatientswithseverepathologicalgamblingandotherimpulsecontroldisorders AT onofrjm amantadineandcognitiveflexibilitydecisionmakinginparkinson39spatientswithseverepathologicalgamblingandotherimpulsecontroldisorders AT digiannantoniom amantadineandcognitiveflexibilitydecisionmakinginparkinson39spatientswithseverepathologicalgamblingandotherimpulsecontroldisorders AT thomasa amantadineandcognitiveflexibilitydecisionmakinginparkinson39spatientswithseverepathologicalgamblingandotherimpulsecontroldisorders |
_version_ |
1718400019745210368 |